KAPPADIONE Drug Patent Profile
✉ Email this page to a colleague
When do Kappadione patents expire, and what generic alternatives are available?
Kappadione is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in KAPPADIONE is menadiol sodium diphosphate. There is one drug master file entry for this compound. Additional details are available on the menadiol sodium diphosphate profile page.
Summary for KAPPADIONE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Patent Applications: | 26 |
Formulation / Manufacturing: | see details |
DailyMed Link: | KAPPADIONE at DailyMed |
US Patents and Regulatory Information for KAPPADIONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | KAPPADIONE | menadiol sodium diphosphate | INJECTABLE;INJECTION | 005725-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |